Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 25 Mar 2024 |
| Novo Nordisk A/S - Articles of Association 2024 | 25 Mar 2024 |
| Resolutions from the Annual General Meeting of Novo Nordisk A/S | 21 Mar 2024 |
| Awiqli® (once-weekly basal insulin icodec) recommended for approval for the treatment of diabetes by the European regulatory authorities | 21 Mar 2024 |
| Novo Nordisk A/S - share repurchase programme | 18 Mar 2024 |